For patients with aggressive B cell lymphomas that have stopped responding to standard therapies, treatment options narrow rapidly and outcomes remain poor. A novel immunotherapy combination targeting two distinct molecular pathways simultaneously may represent a meaningful step forward — and importantly, the trial provides mechanistic data explaining why the pairing works, not just that it does.
This Phase 1 trial evaluated englumafusp alfa, a fusion protein that engages the CD19 antigen on malignant B cells while delivering 4-1BBL co-stimulatory signaling to nearby T cells, in combination with glofitamab, a CD20×CD3 bispecific antibody already known to redirect T cells against lymphoma. The study enrolled patients with relapsed or refractory aggressive B cell non-Hodgkin lymphoma — a population with historically dismal prognoses after multiple prior therapies. The combination demonstrated acceptable safety signals alongside preliminary clinical responses that investigators characterized as encouraging, with the mechanistic profiling supporting the rationale for pairing T cell redirection with co-stimulatory amplification.
The biological logic here is compelling: glofitamab forces T cells into proximity with tumor cells via CD3-CD20 bridging, but T cell activation without adequate co-stimulation can be blunted or short-lived. Englumafusp alfa addresses precisely this gap by delivering 4-1BB agonism locally at the tumor microenvironment through CD19 anchoring, potentially overcoming the exhaustion and anergy that limit single-agent bispecific responses. This mechanistic complementarity distinguishes the combination from empirically paired regimens. Critically, this is Phase 1 data — dose optimization, not efficacy confirmation, is the primary objective. Cohort sizes are small, response rates should be interpreted cautiously, and durability data remain immature. Still, for a heavily pretreated population, any signal of activity alongside manageable toxicity is meaningful. Larger randomized trials will need to establish whether this co-stimulatory strategy translates into survival benefit over existing bispecific monotherapy or CAR-T approaches.